Table S1. Performance of BALF EV-based EGFR genotyping at stage I: sensitivity, specificity, positive and negative predictive value.
| Stage I (N= 36) | Sensitivity, % (95% CI) | Tissue/cytology (+) | Specificity, % (95% CI) | Tissue/cytology (−) | Positive predictive value, % (95% CI) | Negative predictive value, % (95% CI) | ||
|---|---|---|---|---|---|---|---|---|
| BALF EV (+) | BALF EV (−) | BALF EV (+) | BALF EV (−) | |||||
| Solid nodule (N=17) | 42.9 (9.9–81.6) | 3 | 4 | 100 (69.2–100) | 0 | 10 | 100 | 71.4 (56.8–82.6) |
| GGN (N=19) | 30 (6.7–65.3) | 3 | 7 | 88.9 (51.8–99.7) | 1 | 8 | 75 (27.3–96.0) | 53.3 (41.7–64.6) |